Gilead has struck a deal to buy Germany-based Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing toward pivotal ...
Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results